Castle Biosciences Inc (CSTL)
Castle Biosciences - Landmark Study Shows Combination of Castle Biosciences DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
Castle Biosciences - Landmark Study Shows Combination of Castle Biosciences DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak signals • Minimal impact expected **Sentiment:** Neutral (50%) **Content type:** General